Free Trial

BioXcel Therapeutics (BTAI) Stock Forecast & Price Target

$0.54
-0.01 (-1.81%)
(As of 10/9/2024 ET)

BioXcel Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
3

Based on 4 Wall Street analysts who have issued ratings for BioXcel Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for BTAI.

Consensus Price Target

$5.50
914.01% Upside
According to the 4 analysts' twelve-month price targets for BioXcel Therapeutics, the average price target is $5.50. The highest price target for BTAI is $7.00, while the lowest price target for BTAI is $1.00. The average price target represents a forecasted upside of 914.01% from the current price of $0.54.
Get the Latest News and Ratings for BTAI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioXcel Therapeutics and its competitors.

Sign Up

BTAI Analyst Ratings Over Time

TypeCurrent Forecast
10/11/23 to 10/10/24
1 Month Ago
9/11/23 to 9/10/24
3 Months Ago
7/13/23 to 7/12/24
1 Year Ago
10/11/22 to 10/11/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$5.50$5.50$11.80$23.88
Forecasted Upside914.01% Upside918.52% Upside875.21% Upside636.88% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold

BTAI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BTAI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioXcel Therapeutics Stock vs. The Competition

TypeBioXcel TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.79
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside914.01% Upside10,995.04% Upside7.34% Upside
News Sentiment Rating
Negative News

See Recent BTAI News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/6/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00+1,086.22%
8/30/2024Canaccord Genuity Group
1 of 5 stars
 Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00+1,048.09%
8/9/2024UBS Group
4 of 5 stars
 Lower TargetNeutral ➝ Neutral$3.50 ➝ $1.00+32.78%
3/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$8.00 ➝ $7.00+160.22%
10/4/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/23/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral
7/17/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
3/10/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$20.00 ➝ $22.00-10.42%
1/26/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$16.00 ➝ $26.00-16.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:17 AM ET.


BTAI Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for BioXcel Therapeutics is $5.50, with a high forecast of $7.00 and a low forecast of $1.00.

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BTAI shares.

According to analysts, BioXcel Therapeutics's stock has a predicted upside of 914.01% based on their 12-month stock forecasts.

BioXcel Therapeutics has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, and UBS Group in the past 90 days.

Analysts like BioXcel Therapeutics less than other "medical" companies. The consensus rating score for BioXcel Therapeutics is 2.75 while the average consensus rating score for "medical" companies is 2.79. Learn more on how BTAI compares to other companies.


This page (NASDAQ:BTAI) was last updated on 10/10/2024 by MarketBeat.com Staff
From Our Partners